<DOC>
	<DOCNO>NCT02183350</DOCNO>
	<brief_summary>The primary objective current study investigate safety tolerability BI 1356 BS follow administration multiple rise oral dos 1 mg , 2.5 mg , 5 mg , 10 mg 12 day male patient type 2 diabetes .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics BI 1356 BS Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Male patient proven diagnose type 2 diabetes mellitus treat diet exercise one ( two ) oral hypoglycaemic agent besides glitazones Glycosylated haemoglobin A1 ( HbA1c ) ≤ 8.5 % screen patient treat diet exercise and/or one oral hypoglycaemic agent ≤ 8.0 % screen patient treat two oral hypoglycaemic agent Age ≥21 Age ≤65 year BMI ≥18.5 BMI ≤35 kg/m2 ( Body Mass Index ) Caucasian ethnicity Signed date write informed consent prior admission study accordance Good Clinical Practice GCP local legislation Any finding medical examination ( include Blood Pressure ( BP ) , Pulse Rate ( PR ) Electrocardiogram ( ECG ) ) deviate normal acceptable clinical relevance Clinically relevant concomitant disease like renal insufficiency , cardiac insufficiency New York Heart Association ( NYHA ) IIIV , know cardiovascular disease include hypertension &gt; 160/110 mmHg , stroke Transient ischaemic attack ( TIA ) Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder besides type 2 diabetes , hyperlipidaemia medically treat hypertension Diseases central nervous system ( epilepsy ) psychiatric disorder relevant neurological disorder besides polyneuropathy Chronic relevant acute infection ( e.g . Human immunodeficiency virus ( HIV ) , Hepatitis ) History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial except allow comedication Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range acceptable clinical relevance Change drug dosing allow comedication ( antihypertensive agent , acetylic salicylic acid statin ) within last 3 month Any ECG value outside reference range clinical relevance include , limited QRS interval &gt; 120 m QTcB &gt; 450 m QT &gt; 500 m Fasted blood glucose &gt; 240 mg/dl ( =13.3 mmol/L ) two consecutive day washout Serum creatinine upper limit normal screening</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>